Rain Therapeutics Inc expected to post a loss of 69 cents a share - Earnings Preview

Rain Oncology

09/11/2022 02:22

* Rain Therapeutics Inc  RAIN.OQ   RAIN.O  is expected
to show no
change in quarterly revenue when it reports  results on November
10. 
    * 
    * ​Refinitiv's mean analyst estimate for Rain Therapeutics
Inc is
for a loss of 69 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rain
Therapeutics
Inc is $16​, above​ its last closing price of $5.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.67       -0.66      -0.66     Met     0.6
 Mar. 31 2022  -0.69       -0.70      -0.66     Beat    5.5
 Dec. 31 2021  -0.53       -0.56      -0.68     Missed  -20.7​
 Sep. 30 2021  -0.41       -0.48      -0.70     Missed  -45.5
 ​​Jun.        -0.60       -0.60      -0.39     Beat    34.8
 30 2021                                                
 Mar. 31 2021  -0.78       -0.78      -1.93     Missed  -147.4
                                                        ​
 This summary was machine generated November 9 at 02:22 GMT.  All
figures in US dollars  unless otherwise stated